GLP-1 Myths vs Facts: Common Claims Debunked

GLP-1 medicines have entered the mainstream conversation at a speed that few pharmaceutical developments ever do. They've gone from being a niche diabetes treatment to front-page news, social media debates, and dinner-table discussions — all within a few years.

That kind of rapid cultural saturation creates fertile ground for myths. When a topic generates both intense hope and intense scepticism, and when the science is genuinely complex, oversimplifications spread faster than nuance ever can.

Some of the myths about GLP-1 medicines are rooted in outdated information. Others are genuine misunderstandings of how the drugs work. And some are simply the result of strong opinions filling the gap where evidence should be.

This article takes the most common claims you'll encounter — online, in conversations, or even from well-meaning friends and family — and examines what the evidence actually says. The tone here is not combative. The goal is clarity. Some of these "myths" contain a kernel of truth that deserves honest discussion, and we'll address that too.

The claim: GLP-1 medicines simply kill your appetite. They're just a fancy way to eat less.

The reality: Appetite reduction is one of the effects — but calling GLP-1 medicines "just appetite suppressants" is like calling a smartphone "just a calculator." It's technically not wrong, but it misses most of what's actually happening.

GLP-1 receptor agonists work through multiple mechanisms simultaneously:

• Appetite regulation: They act on brain centres involved in hunger and satiety, reducing the constant "food noise" many patients experience.
• Delayed gastric emptying: Food stays in the stomach longer, producing a longer feeling of fullness after meals.
• Blood sugar stabilisation: They improve insulin release and reduce glucagon, preventing the blood sugar spikes and crashes that trigger cravings.
• Potential effects on reward pathways: Emerging research suggests GLP-1 medicines may modulate the brain's reward centres, reducing the compulsive drive to eat beyond physical hunger.

Traditional appetite suppressants — like the older stimulant-based drugs — worked on a single pathway and carried significant cardiovascular and addiction risks. GLP-1 medicines are a fundamentally different class of drug, acting on the body's own incretin system in ways that address the biology of overeating, not just the symptom of hunger.

Calling them appetite suppressants doesn't just oversimplify — it actively misleads patients about how these medicines work and what they can expect.

The claim: GLP-1 medicines only work while you take them. The moment you stop, you'll regain every kilogram.

The reality: This myth contains an important truth — but draws the wrong conclusion from it.

It is true that weight regain after discontinuation is common. Studies, including the STEP 1 extension trial, have shown that patients who stopped semaglutide after 68 weeks regained approximately two-thirds of their lost weight within the following year. This is real, and patients should know about it.

But the conclusion that "it doesn't really work" or "the treatment is pointless" doesn't follow. Here's why:

• Obesity is a chronic condition. Just as stopping blood pressure medication can cause blood pressure to rise again, stopping obesity medication can allow weight to return. This doesn't mean the medication failed — it means the underlying condition is still present.
• The treatment model matters. For many patients, GLP-1 medicines are a long-term or maintenance treatment, not a short course. The expectation of "take it for six months and be cured" is based on a misunderstanding of how chronic metabolic conditions work.
• Some patients maintain significant weight loss. Those who combine medication with sustained dietary changes, physical activity, and ongoing medical support tend to retain more of their weight loss even after tapering or stopping.
• Research on maintenance strategies is ongoing. Clinicians are actively studying how to transition patients off full-dose GLP-1 therapy while preserving outcomes — including lower maintenance doses, lifestyle interventions, and combined approaches.

The honest answer is: weight regain is a risk, and managing that risk is part of the treatment plan. That's very different from "it's all pointless."

The claim: People taking GLP-1 medicines are taking a shortcut instead of eating better and exercising.

The reality: This myth is perhaps the most damaging, because it carries moral judgement rather than medical reasoning.

The implication is that weight management is simply a matter of discipline, and that using medication means you've "given up" on doing it the "right" way. This view is not supported by modern medical science.

Here's what the evidence shows:

• Obesity has strong biological drivers. Genetics, hormonal signalling, gut microbiome composition, neurological reward pathways, and metabolic adaptation all play significant roles in weight. These factors are not overridden by willpower alone.
• Lifestyle changes alone have limited long-term success for many patients. Studies consistently show that sustained weight loss of more than 5 to 10 percent through diet and exercise alone is achieved by a small minority of people over 5 years. This is not because people aren't trying hard enough — it's because the body actively resists sustained weight loss through metabolic adaptation and hormonal changes that increase hunger and decrease energy expenditure.
• GLP-1 medicines work alongside lifestyle changes, not instead of them. Every clinical trial that demonstrated the effectiveness of semaglutide included lifestyle intervention (diet counselling, exercise guidance) as a standard component for all participants. The medication creates the physiological conditions — reduced hunger, stable blood sugar, fewer cravings — that make sustainable lifestyle changes more achievable.

No one says a patient with high blood pressure is taking "the easy way out" by using medication. No one says a patient with type 2 diabetes is being lazy by using insulin. The judgement around obesity medication reflects stigma, not science.

The claim: GLP-1 medicines make you lose muscle instead of fat. The weight you lose isn't healthy weight loss.

The reality: This concern isn't baseless, but the way it's presented as a myth typically exaggerates the issue and ignores important context.

Any significant weight loss — regardless of how it happens — involves some loss of lean mass. This is true for surgical weight loss, for very-low-calorie diets, and for GLP-1-mediated weight loss. It's a physiological reality, not a unique flaw of these medicines.

What matters is the proportion of lean mass lost relative to fat mass. In the STEP trials for semaglutide, the majority of weight lost was fat mass. Lean mass loss did occur, but at proportions generally consistent with what's seen in other weight loss methods of similar magnitude.

What Can Be Done About It?

• Adequate protein intake. Patients on GLP-1 medicines are advised to consume sufficient protein (typically 1.2 to 1.6 grams per kilogram of body weight per day) to support muscle preservation.
• Resistance training. Incorporating strength or resistance exercises at least 2 to 3 times per week has been shown to significantly reduce lean mass loss during weight loss — regardless of the method used.
• Medical monitoring. Clinicians can track body composition and adjust treatment plans accordingly.

The responsible message is: lean mass loss is a real consideration that should be actively managed through nutrition and exercise — not a reason to avoid effective treatment for obesity.

The claim: GLP-1 medicines are being used by people who just want to look thinner. It's a cosmetic trend, not real medicine.

The reality: GLP-1 receptor agonists were developed for — and are approved for — serious medical conditions: type 2 diabetes and chronic weight management in patients with obesity or overweight with weight-related comorbidities.

The clinical criteria for these prescriptions are specific:

• For weight management, semaglutide (Wegovy) is indicated for adults with a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related condition such as type 2 diabetes, high blood pressure, or dyslipidaemia.
• Prescribing requires a medical evaluation, not just a cosmetic preference.

It is true that media coverage has sometimes focused on celebrity use and dramatic before-and-after stories, which can create the impression that these are "vanity drugs." But the clinical reality is that the majority of patients using GLP-1 medicines are managing real metabolic health conditions — conditions that increase risk of heart disease, stroke, joint damage, sleep apnoea, and more.

There is also emerging evidence from the SELECT trial that semaglutide reduces major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by 20 percent in overweight or obese adults with existing cardiovascular disease — regardless of diabetes status. This is not a cosmetic outcome. It is a potentially life-saving one.

The conversation about appropriate prescribing and equitable access is legitimate and important. But dismissing GLP-1 medicines as vanity treatments ignores the medical reality of the patients who need them most.

The claim: These are new drugs. We don't know the long-term effects. They haven't been around long enough to trust.

The reality: GLP-1 receptor agonists are not new. The first GLP-1 RA (exenatide, brand name Byetta) was approved by the FDA in 2005 — over two decades ago. Liraglutide (Victoza) followed in 2010. Semaglutide (Ozempic) was approved in 2017, with the higher-dose weight management formulation (Wegovy) approved in 2021.

The GLP-1 receptor agonist drug class has been in continuous clinical use and ongoing study for over 20 years. During that time:

• Millions of patients worldwide have been prescribed these medicines.
• Large-scale cardiovascular outcome trials (including SUSTAIN-6, PIONEER 6, and SELECT) have been completed, providing extensive safety data.
• Post-marketing surveillance — ongoing monitoring of side effects and safety signals after a drug enters the market — has been active for years across multiple countries.

That said, the higher doses used specifically for weight management (as opposed to diabetes) have been in widespread use for a shorter period, and long-term data at those specific doses is still accumulating. This is a legitimate area of ongoing study, and no responsible clinician would claim that every long-term question has been fully answered.

The balanced position is: GLP-1 medicines as a class have an extensive safety record spanning over two decades. Specific formulations and dosing for weight management are newer, and long-term follow-up continues. This is how evidence-based medicine works — it accumulates, and patients should be informed about both what we know and what we're still learning.

The claim: If you're taking a GLP-1 medicine, you don't need to worry about what you eat or whether you exercise. The drug does the work for you.

The reality: This is one of the most persistent misconceptions — and it can genuinely undermine treatment outcomes.

GLP-1 medicines are designed to be used alongside lifestyle modifications, not instead of them. Every major clinical trial — including the STEP, SUSTAIN, and SURPASS programmes — enrolled patients in structured lifestyle interventions alongside the medication. The impressive results reported in these trials reflect both components working together.

Here's why lifestyle still matters:

• Nutrition quality affects health outcomes beyond weight. Even if the medication reduces your appetite, the quality of what you eat when you do eat matters. Adequate protein preserves muscle, sufficient fibre supports digestion, and proper hydration prevents the constipation that many patients experience. Eating less of the same processed food isn't optimal — eating better is.
• Physical activity preserves lean mass. As discussed earlier, weight loss — by any method — involves some muscle loss. Resistance training and regular movement counteract this and improve cardiovascular health, bone density, mental health, and metabolic function.
• Sustainable habits improve long-term outcomes. If and when a patient reduces or stops their medication, the lifestyle changes they've built become the primary mechanism for maintaining their results. Patients who relied entirely on the drug without building new habits are more vulnerable to full weight regain.

The medication creates a window of opportunity — reduced hunger, fewer cravings, more stable energy — that makes building healthy habits more achievable. But you still need to walk through that window.

Honest education means acknowledging what we don't fully know yet. Here are areas where the evidence is still developing:

• Very long-term outcomes at weight management doses. While GLP-1 medicines have been used for diabetes for over 20 years, higher doses specifically for weight management have been widely prescribed for a shorter period. Multi-decade data at these doses is still being collected.
• Optimal duration of treatment. How long should a patient remain on a GLP-1 medicine? Should it be lifelong for some patients? Is there an effective tapering protocol? These are active areas of clinical research with no universal answer yet.
• Individual variability in response. Some patients respond dramatically to GLP-1 medicines; others see more modest results. The factors that predict which patients will respond best are still being studied.
• Effects on specific populations. Data in adolescents, elderly patients, patients with certain comorbidities, and patients in specific ethnic and genetic populations continues to expand. Treatment decisions for these groups require especially careful clinical judgement.
• Interactions with other emerging treatments. As new obesity medicines enter the market (dual and triple agonists, amylin analogues, etc.), the best combinations and sequencing strategies are still being worked out.

Uncertainty is not a reason to avoid treatment. It is a reason to work with a knowledgeable clinician who can help you weigh the known benefits against the open questions, based on your specific situation.

Social media, forums, and even some news outlets can be unreliable sources for medical information about GLP-1 medicines. Here are a few principles to help you evaluate what you read:

• Check the source. Is the claim coming from a peer-reviewed study, a regulatory agency (FDA, EMA, CDSCO), or a major academic medical centre? Or is it a personal anecdote, a social media post, or a wellness influencer?
• Beware of absolute language. "Always," "never," "everyone," "guaranteed" — these words are red flags in medical discussions. Human biology is variable, and responsible medical claims almost always include qualifiers.
• Look for cited evidence. Trustworthy health content references specific studies, prescribing information, or clinical guidelines. If an article makes strong claims with no citations, treat it with scepticism.
• Be cautious of before-and-after stories. Individual patient experiences are real and valid, but they are not evidence. One person's dramatic result doesn't predict yours, and one person's bad experience doesn't represent the drug's safety profile.
• Ask your doctor. If something you read concerns or excites you, bring it to your next consultation. A qualified clinician can assess whether the information is accurate and whether it applies to your situation.

This article is for informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. The information presented here is based on published clinical evidence and official prescribing information available at the time of writing. Medical evidence evolves — consult a qualified healthcare provider for the most current guidance specific to your situation. Individual responses to GLP-1 medicines vary, and treatment decisions should always be made in consultation with your prescribing doctor. Zelta facilitates consultations with licensed physicians — all treatment decisions are made by your doctor based on your individual health profile.